Pharmac says there's not enough evidence to justify spending 30 million dollars a year on a promising new melanoma drug.
Show status: Off air
Recent stories from Checkpoint
Get the RNZ app
for easy access to all your favourite programmes
for easy access to all your favourite programmes
